Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00625001

Enrollment

Registered

2008-02-28

Start date

1994-11-30

Completion date

2010-06-30

Last updated

2008-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Turner Syndrome

Keywords

Turner Syndrome, bone mineral density, estrogen replacement therapy, dual energy x-ray absorptiometry

Brief summary

Turner Syndrome (TS) is associated with osteopenia and osteoporosis. Reduced bone mineral density (BMD) and increased risk of fractures are present in many younger and middle-aged women with TS. The objective is therefore to describe longitudinal changes in BMD in TS. The study is an observational follow-up study. Examinations at baseline, after 5 and 10 years. Bone mineral density is measured by dual energy x-ray absorptiometry (DEXA) and bone turnover by bone markers. Main Outcome Measures: Bone mineral density (BMD; grams/ square centimetre) were measured at lumbar spine, hip and the non-dominant forearm.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Turner syndrome verified by karyotyping

Exclusion criteria

* untreated hypothyroidism or hyperthyroidism * present or past malignant diseases * clinical liver disease * treatment with drugs known to interfere with bone metabolism (e.g. glucocorticoids)

Design outcomes

Primary

Measure	Time frame
Bone Mineral Density in columna lumbalis, collum femoris and distal ulnae Bone mineral density (BMD; grams/ square centimetre) were measured at lumbar spine, hip and the non-dominant forearm.	Evey 5 years

Outcome results